Please join Repare Therapeutics in welcoming Dr. Steven H. Stein to our Board of Directors, effective June 17, 2024. Dr. Stein currently serves as the Chief Medical Officer of Incyte Corporation, a position he has held since March 2015. Prior to joining Incyte, Dr. Stein has held leadership positions at Novartis Oncology, GlaxoSmithKline, and Kura Oncology. He has authored more than 100 scientific papers and presentations and is an Adjunct Assistant Professor in the University of Pennsylvania School of Medicine.
Repare Therapeutics’ Post
More Relevant Posts
-
Life Sciences consulting leader with 20+ years of experience; President of BioKatalyst, a non-profit biopharma executives association
See our latest Oncology Pulse! (Ironman vs. Superman?) Meet the Bluestar oncology team at ASCO!
ADCs and radiopharmaceuticals have re-emerged as modalities of high interest in oncology licensing and acquisition – will they be the next wave of breakthroughs or represent a flight to safety in light of the challenges of finding the next hot target and the IRA? Here's a link to our latest Oncology Pulse: https://lnkd.in/gJ4xUFUB Also, ASCO24 is one week away, and abstracts drop today. Our team is looking forward to sifting through the data to understand the implications. We hope to see you in Chicago!
To view or add a comment, sign in
-
The antibody–drug conjugate (ADC) landscape is rapidly evolving and has become a significant therapeutic modality in oncology. The publication offers a nice overview of the ADC landscape. https://lnkd.in/eSGNKSEB
The antibody–drug conjugate landscape
nature.com
To view or add a comment, sign in
-
Biosimilars news is heating up! This week's top stories: interchangeability updates, new approvals, and overcoming barriers to biosimilars in oncology. Click the link below to watch the video of the top 5 articles of the week to learn more about these and other biosimilar advancements! https://lnkd.in/eFKnXkwQ
To view or add a comment, sign in
-
-
Dr. Roy Baynes of Eikon Therapeutics joined us to discuss his process of developing pembrolizumab, also known as Keytruda. Applying his experience as CMO and Head of Development at Merck, he explains what it takes to successfully develop an oncology therapeutic. Read the article here: https://lnkd.in/eCwvmyvV! #ClinicalTrials #DrugDevelopment #Keytruda
To view or add a comment, sign in
-
-
We analyzed pivotal clinical trials for oncology drugs approved by the FDA in the past few years, focusing on their features and associated costs. Here's what we found: Trials with a primary endpoint of Overall Survival cost 2-3x a PFS study costs (~$80M).
To view or add a comment, sign in
-
-
Randomized controlled clinical trials are regulatory agencies’ preferred approach for registrational studies in new drug and biologics development. However, there are circumstances in oncology when a single-arm trial may be more appropriate. Check the Citeline summary on the key Veristat presentation on the topic > https://bit.ly/45GAIwv #singlearmtrial #oncology
Single-Arm Studies for Use as a Registrational Study in Oncology Article
veristat.com
To view or add a comment, sign in
-
Considering the Totality of Efficacy and Safety Data to Aide Registrational Trial Designs: Stacy Shord, PharmD, Jin Y. Jin, PhD, and Scott Van Wart, PhD, will address this topic in a session at the FDA-AACR public workshop on Optimizing Dosages for Oncology Drug Products (Feb 15-16). Learn more: https://bit.ly/3OJgqw1 #AACRSciencePolicy
To view or add a comment, sign in
-
-
Read now the latest edition of Pharma insights! In this edition, you'll dive into the complexities of cancer and understand the path forward in oncology drug development! Plus, stay updated with all the information about our upcoming webinar on June 25. Don't miss out! Click here: https://ow.ly/r2We30sCYug #CrodaPharma #PharmaInsights #EmpoweringBiologicsDelivery
To view or add a comment, sign in
-
-
Read now the latest edition of Pharma insights! In this edition, you'll dive into the complexities of cancer and understand the path forward in oncology drug development! Plus, stay updated with all the information about our upcoming webinar on June 25. Don't miss out! Click here: https://ow.ly/WCcT30sCWYk #CrodaPharma #PharmaInsights #EmpoweringBiologicsDelivery
To view or add a comment, sign in
-
-
Global Precision Oncology Market Trends and Growth Opportunities Report 2023: Public-private Partnerships Will Propel Access and Adoption of Precision Oncology Enhancing Integrated Solutions: DUBLIN, Dec. 8, 2023 /PRNewswire/ -- The "Global Precision Oncology Market Trends and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. This study highlights current technological trends and emphasizes the interdisciplinary efforts underway to ensure that a...
To view or add a comment, sign in